Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
•
Internal Medicine
Do you use metronidazole twice daily dosing for routine anaerobic coverage such as non-CNS, H. pylori, C. diff, or parasitic infections?
Related Questions
Do routinely recommend antifungal prophylaxis for non-transplant patients who have been diagnosed and completed treatment for possible/probable pulmonary aspergillosis and who will need varying degrees of ongoing immunosuppression?
Would you consider use of doxycycline for deep-seated pasteurella multicoda infection in a patient with contraindications to first-line antimicrobial agents?
Do you routinely recommend transition to dual PO antibiotic coverage for strep species and MRSA, for patients with purulent cellulitis and in the absence of culture data?
In a patient with CIED lead infection and bacteremia who had blood cultures cleared before CIED extraction, do we still need 72 hrs of documented negative blood cultures obtained post extraction to consider reimplantation and can we do same-time extraction and reimplantation?
Do you routinely continue dual antibiotic coverage or de-escalate to monotherapy based on peritoneal fluid culture sensitivities in patients with relapsing pseudomonas aeruginosa peritoneal dialysis peritonitis after peritoneal catheter removal?
Do you switch to an alternative agent for C difficile colitis for a patient with suspected infection and positive testing who continues to have >3 watery bowel movements daily despite multiple days of oral vancomycin treatment?
What are your top takeaways from IDWeek 2025?
When would you consider long-term suppressive antibiotic therapy in patients with chronic or recurrent bacterial prostatitis who continue to experience symptoms despite multiple courses of antibiotics?
How long do you typically treat mixed infections involving Actinomyces such as empyema or abdominal abscesses when adequate source control has been achieved?
How does trimethoprim-sulfamethoxazole's efficacy against S. pyogenes influence your empirical treatment of skin infections in regions with high resistance rates?
